Minneapolis, MN, Sept. 27, 2016 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing the PURE EP(TM) System, a novel cardiac electrophysiology (EP) signal acquisition and analysis system, today announced it will present at the September 28th 2016, fifth annual OktoberINVESTfest, presented by Invest in Bavaria in partnership with Joseph Gunnar & Co. BioSig will present at 5:20pm ET at the New York Academy of Sciences at 7 World Trade Center in New York, if interested in attending please register at www.oktoberINVESTfest.com.
OktoberINVESTFest brings together US and German investors, innovators, industry leaders, and 43 select innovative US and German small and microcap companies as well as some private growth and early stage investment opportunities. The resulting business and investment ties will deepen transatlantic relations and encourage economic and scientific exchange.
Keynoter Kevin Harris, Senior Economist and North American Director of Roubini Global Economics will lend in insight into investing in Europe. Other spotlight talks include: Dr. Joann Halpern, Director of the German Center for Research and Innovation giving advice on European grant programs and research partnerships and the much awaited discussion on the Cancer MoonShot initiative by committee members: Dr. Dvorit Samid, Head of Global Oncology Medical Affairs Program at NantKwest and Dr David Sans, Head of Equity Research at Joseph Gunnar & Co. Likewise we will hear about Smart Factories and the Industrial internet from experts at IBM, Draper Labs and Bavarian global player Siemens.
“OktoberINVESTFest is an example of how Invest in Bavaria is continuously working to provide US companies with direct access to expansion opportunities in the State of Bavaria,” said Jan Danisman, Executive Director at Bavarian US Offices for Economic Development. “At the same time, we are introducing innovative Bavarian companies to US investors and partners, thus working to solidify relationships between the two markets.”
About BioSig Technologies
BioSig Technologies is a medical device company that is developing a proprietary technology platform designed to improve the $4 billion EP marketplace (1) (biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System.
The PURE EP(TM) System is a surface electrocardiogram and intracardiac multichannel signal acquisition and analysis system engineered to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing clarity of data which may be used to guide the electrophysiologists in identifying ablation targets – areas of tissue to treat that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1), making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig has partnered with Minnetronix on technology development and is working toward a FDA 510(k) clearance for the PURE EP System. The Company has achieved proof of concept validation and tested its prototype at the University of California at Los Angeles (UCLA) Cardiac Arrhythmia Center; and, has performed pre-clinical studies at Mayo Clinic in Minnesota. Additionally, an Advanced Research Program at Mayo Clinic began in June 2016. The Company is also collaborating with other prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UH Case Medical Center in Cleveland, Ohio and Mount Sinai Medical Center in New York.
(1) Electrophysiology Devices Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019
(2) HRI 2013 “Global Opportunities in Medical Devices & Diagnostics” report; triangulation of multiple sources; AF includes left atrial tachycardia, left WPW, left atrial flutter.
About Invest In Bavaria
The conference is hosted by Invest in Bavaria , the investment and location marketing organization of the German State of Bavaria’s Ministry for Economic Affairs, Media, Energy and Technology. Bavaria, with capital city Munich, Europe’s top tech hub, Germany’s #1 in biotech and #1 in medtech is home to global players such as BMW, Siemens, Wacker Chemie, Allianz and Adidas along with 1200 US companies. Invest in Bavaria supports companies from around the world to find ideal locations to set up businesses and/or identify investment opportunities in Bavaria. The organization has played a vital role in connecting US investors and business leaders with Bavaria’s strategic and competitive advantages, in addition to providing them with cost-free, confidential professional services to assist in their investment and site selection process. For additional information, please visit www.bavaria.org.
About Joseph Gunnar & Co., LLC
Joseph Gunnar & Co is a full service broker dealer dedicated to assisting investors achieve their financial goals by providing a full array of investment products and vehicles to private and corporate clients. It was founded in 1997 by its current CEO and Chairman. The Global Equity Capital Markets team is dedicated to IPOs, secondary public offerings, PIPEs, private placements, SPACs and advisory services. It ranked #1 in number of US equity underwriting transactions facilitated for deals up to $50 million in size since the start of 2013 and in number of US IPO transactions facilitated for deals up to $60 million in size since the start of 2013. Joseph Gunnar also has Debt Capital Market capabilities to facilitate non-dilutive financings for private and public companies and an affiliate, Buttonwood Group Advisors, which manages a family of private investment funds that provide retail and institutional investors access to investments in rapid-growth, pre-IPO companies. For additional information, please visit www.josephgunnar.com.
CONTACT: Investor Relations: Brian McLaughlin BioSig Technologies, Inc. email@example.com 917-370-9817 Robert Haag IRTH Communications BSGM@irthcommunications.com 866-976-4784